Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target. The firm noted that the company's two mid-stage programs show clinical activity and have peak sales potential that exceed $1 billion. Roth also highlighted that ARCT shares are trading close to their cash value, effectively pricing in a 0% chance of success for these assets, which makes ARCT potentially one of the most mispriced stocks in rare disease. Similarly, earlier on January 6, Citigroup lowered its price target for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) from $9 to $7 and maintained a Neutral rating. The firm highlighted opportunities in SMID-cap biotech for 2026, particularly in companies at the commercial or near-commercial stage. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company developing mRNA-based vaccines and RNA therapeutics using proprietary delivery technologies. Its pipeline targets infectious diseases like CO
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.MarketBeat
- 1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/8/26 - Form SCHEDULE
- 12/30/25 - Form S-3
- ARCT's page on the SEC website